share_log

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July

可能在7月份帶來最大漲幅的五大醫療保健股
Benzinga ·  2023/07/05 20:51

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

醫療保健領域超賣次數最多的股票爲買入被低估的公司提供了機會。

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

RSI是一種動量指標，它比較了股票在價格上漲的日子裏的強度與價格下跌時的強度。與股票的價格走勢相比，它可以讓交易者更好地瞭解股票在短期內的表現。當 RSI 低於 30 時，資產通常被視爲超賣。

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

以下是該行業主要超賣參與者的最新名單，RSI接近或低於30。

Cibus, Inc. (NASDAQ:CBUS)

Cibus, Inc. （納斯達克股票代碼：CBUS）

  • Cibus, recently announced the closing of its previously announced merger with Calyxt, Inc. "2023 has already been a transformational year for Cibus, and a large part of the transformation is the combination with Calyxt. Together, the combined company has over 1,000 patents issued or pending covering a broad range of fundamental enabling technology in gene editing in agriculture," said Rory Riggs, Chief Executive Officer of Cibus. The company's stock has a 52-week low of $6.25 .
  • RSI Value: 26.56
  • CBUS Price Action: Shares of Cibus fell 4.9% to close at $9.99 on Monday.
  • Cibus最近宣佈結束先前宣佈的與Calyxt, Inc.的合併。“2023年對Cibus來說已經是變革性的一年，轉型的很大一部分是與Calyxt的合併。合併後的公司共擁有1,000多項已頒發或正在申請的專利，涵蓋了農業基因編輯方面的各種基本使能技術。” Cibus首席執行官羅裏·裏格斯說。該公司的股票有 52 周低點爲 6.25 美元 。
  • RSI 值： 26.56
  • CBUS 價格走勢： 週一，Cibus的股價下跌4.9％，收於9.99美元。

Panbela Therapeutics, Inc. (NASDAQ:PBLA)

Panbela Therapeutics, Inc （納斯達克股票代碼：PBLA）

  • Panbela Therapeutics has been granted European patent number EP3746425 titled "Methods For Producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol (The Company's Lead Investigational Product Sbp-101 For The Treatment Of Metastatic Pancreatic Cancer)." It has a 52-week low of $1.80.
  • RSI Value: 27.31
  • PBLA Price Action: Shares of Panbela Therapeutics fell 4.8% to close at $2.19 on Monday.
  • Panbela Therapeutics已獲得歐洲專利，編號 EP3746425，標題爲 “生產方法 (6s,15s) -3,8,13,18-tetrazaicosane-6,15-diol（該公司治療轉移性胰腺癌的主要研究產品Sbp-101）”。它 創下 52 周低點 1.80 美元。
  • RSI 值： 27.31
  • PBLA 價格走勢： 週一，Panbela Therapeutics的股價下跌4.8％，收於2.19美元。

Vor Biopharma Inc. (NASDAQ:VOR)

Vor Biopharma Inc （納斯達克股票代碼：VOR）

  • Vor Biopharma recently presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in acute myeloid leukemia patients. The company's stock has a 52-week low of $2.93.
  • RSI Value: 29.06
  • VOR Price Action: Shares of Vor Biopharma dipped 4.2% to close at $2.96 on Monday.
  • Vor Biopharma最近公佈了在急性髓系白血病患者trem-cel（前身爲 VOR33）的 VBP101 1/2a 期研究中接受治療的患者的最新數據。該公司的股票爲52周 低點爲2.93美元。
  • RSI 值： 29.06
  • VOR 價格走勢： 週一，Vor Biopharma的股價下跌4.2％，收於2.96美元。

Innovative Eyewear, Inc. (NASDAQ:LUCY)

創新眼鏡有限公司 （納斯達克股票代碼：LUCY）

  • Innovative Eyewear recently announced a new retail partnership with PRIVATO duty-free to create Lucyd Eyewear retail showcase in seven of its airport-based locations. The company's 52-week low is $0.70.
  • RSI Value: 27.98
  • LUCY Price Action: Shares of Innovative Eyewear fell 3.7% to close at $0.8611 on Monday.
  • Innovative Eyewear最近宣佈與PRIVATO免稅店建立新的零售合作伙伴關係，在其七個機場地點創建Lucyd Eyewear零售展示櫃。該公司的52周低點爲0.70美元。
  • RSI 值： 27.98
  • LUCY 價格走勢： 週一，Innovative Eyewear的股價下跌3.7％，收於0.8611美元。

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)

Bellerophon Thareutics, Inc （納斯達克股票代碼：BLPH）

  • Bellerophon Therapeutics approved reduction-in-force of substantially all of its employees, including its executive officers. The company has a 52-week low of $0.65.
  • RSI Value: 20.87
  • BLPH Price Action: Shares of Bellerophon Therapeutics fell 2.6% to close at $0.6723 on Monday.
  • Bellerophon Therapeutics批准裁減其幾乎所有員工，包括其執行官。該公司 創下 52 周低點 0.65 美元。
  • RSI 值： 20.87
  • BLPH 價格走勢： 週一，Bellerophon Therapeutics的股價下跌2.6％，收於0.6723美元。

Read More: Investor Sentiment Declines Ahead Of Fed Minutes

閱讀更多： 美聯儲會議紀要前投資者情緒下降

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論